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Aspirin desensitization in a woman with inherited
thrombophilia and recurrent miscarriage
Summary
Women with inherited thrombophilia and recurrent miscarriage might benefit from
preconceptional antiagreggation with low-dose acetylsalicylic acid (ASA), but concerns
about severe adverse reactions may prevent physicians from performing this treatment
in patients with ASA hypersensitivity. We report the first known case of ASA desensi-
tization in a 41-year-old woman with inherited thrombophilia, who had homozygos-
ity (4G/4G polymorphism) of the plasminogen activator inhibitor-1 (PAI-1) gene
and first trimester recurrent miscarriage, and had previously presented with anaphy-
laxis to ASA. Desensitization was completed despite one self-limited adverse reaction,
and the patient has maintained a daily ASA intake of 100mg with good tolerance.
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Recurrent miscarriage, defined as three or more first
trimester pregnancy losses, is devastating for women and
their families. Women with inherited thrombophilia and
recurrent miscarriage might benefit from preconceptional
antiaggregation with low-dose acetylsalicylic acid (ASA),
but concerns about severe adverse reactions may prevent
physicians from performing this treatment in patients
with ASA hypersensitivity (1-3). Desensitization to ASA,
commonly known as aspirin, is an essential procedure in
patients with ASA hypersensitivity who need chronic
treatment with this drug. It was first described in 1922 by
Widal et al. (4) and is most frequently performed for the
treatment and prophylaxis of cardiovascular diseases and
in aspirin-exacerbated respiratory disease (5-9). It has also
been described before or during pregnancy in women
with antiphospholipid syndrome (10), but to our knowl-
edge it has not been previously held in other throm-
bophilic diseases.
We present the case of a 41-year-old woman with three
consecutive miscarriages before 8 weeks of pregnancy, in
whom the study for thrombophilia revealed an inherited
thrombophilia, with exclusion of other causes including
antiphospholipid syndrome. Genotyping analysis showed
homozygosity (4G/4G polymorphism) for the plasmino-
gen activator inhibitor-1 (PAI-1), which results in elevat-
ed PAI-1 concentrations and decreased fibrinolysis, and is
associated with a greater risk of thromboembolic events
and recurrent miscarriages (11). She has an intermittent
allergic rhinitis with sensitization to grass pollens. Six
years prior, she experienced an anaphylactic reaction with
generalized urticaria and respiratory distress immediately
on taking a non-specified dose of ASA. Afterward she
had a cutaneous reaction with generalized urticaria within
30 minutes of intake of ibuprofen 200 mg. Both reactions
required hospital attendance, with resolution after being
medicated with anti-histamine and corticosteroid. She
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tolerates paracetamol and preferential COX-2 inhibitors
non-steroidal anti-inflammatory drugs, nimesulide and
meloxicam. As ASA in low-dose is the best therapeutic
option for antiaggregation during pregnancy (1-3, 10), the
patient was referred to our Immunoallergy Department
for ASA desensitization before the next pregnancy.
In May 2011 we obtained the patient’s written informed
consent, and the ASA desensitization was carried out in
hospital setting using increasing oral doses of ASA, with a
starting dose of 0.1mg, following the protocol presented in
table 1, modified from those of Rossini et al. (8) and Wong
et al. (5). The oral desensitization was performed with 8 se-
quential doses of ASA (0.1, 1, 5, 10, 20, 40, 75 and 100
mg); doses were increased every 30 minutes, with a 120
minute interval before the last dose. Patient’s blood pres-
sure, cardiac rate and oxygen saturation were regularly mea-
sured, and cutaneous, naso-ocular, and pulmonary reactions
were monitored closely, with spirometric surveillance before
initiation, after each step and before hospital discharge.
Within 15 minutes of 10 mg ASA oral administration,
the patient reported rhinitis and a 10% fall from baseline
in the forced expiratory volume in one second (FEV1)
from 3.14 to 2.83 liters, and a 17.4% fall in the maximum
midexpiratory flow (MMEF75/25) from 3.21 to 2.65
liters, with spontaneous improvement and clinical and
spirometrical resolution in 30 minutes, thus confirming
ASA hypersensitivity and delaying the next administra-
tion to 90 minutes instead of 30 minutes later. The pa-
tient completed the desensitization protocol in 6 hours
with a total cumulative dose of 251.1 mg of ASA and was
discharged from the hospital after 2 hours’ surveillance.
She has since maintained a daily ASA intake of 100mg in
a single dose with good tolerance.
To our knowledge this is the first reported case of an
ASA desensitization performed in a women with an in-
herited thrombophilia, in this case a homozygosity of the
PAI-1 gene. It is estimated that 5% of women of repro-
ductive age have two or more recurrent pregnancy losses
and around 1% have three or more losses. Acquired
thrombophilia, as antiphospholipid syndrome, as well as
inherited thrombophilia, may benefit from antiaggrega-
tion with low-dose ASA therapy, alone or in association
with low molecular weight heparin (1-3, 12), meaning in-
herited thrombophilia with recurrent miscarriage could be
included in the indications for ASA desensitization in
woman with ASA hypersensitivity.
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Table 1 - ASA desensitization protocol [modified from Rossini
et al. (8) and Wong et al. (5)]
Time (min) Dose (mg) Cumulative dose (mg)
0 0.1 0.1
30 1.0 1.1
60 5.0 6.1
90 10.0 16.1
*180 20.0 36.1
210 40.0 76.1
240 75.0 151.1
360 100.0 251.1
* Time adjustment due to previous reaction
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